Pura Vida Investments’s Crescent Biopharma CBIO Stock Holding History

Pura Vida Investments’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,766	Closed	-$535K	–	120
2022 Q4	$535K	Buy	+1,766	New	+$260K	0.03%	164

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Pura Vida Investments's CBIO Position: Q1 2023 in Review

Pura Vida Investments sold out of Crescent Biopharma (CBIO) in Q1 2023, closing a stake of 316 shares — an estimated $95.8K sold.

Pura Vida Investments first reported a position in CBIO in Q1 2022 and held it in 2 quarters. The position peaked at $100K in Q1 2022. 54 funds tracked by Wall St. Rank hold CBIO as of Q1 2023.

Pura Vida Investments reported no remaining Crescent Biopharma position as of Q1 2023 after selling out during the quarter.
Pura Vida Investments sold 316 Crescent Biopharma shares in Q1 2023, an estimated $95.8K.
Pura Vida Investments first reported a position in Crescent Biopharma in Q1 2022 and held it in 2 quarters.
Pura Vida Investments's Crescent Biopharma position peaked at $100K in Q1 2022.
54 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.